Prezcobix (cobicistat, darunavir and cobicistat, darunavir ethanolate)
New dosage form
- Region
- 🇺🇸 US
- Active substance
- cobicistat, darunavir and cobicistat, darunavir ethanolate
- Company
- Janssen Prods
- Status
- Approved
- FDA approval
- Fri 27 Feb 2026
- Designations
- New dosage form
- Application
- NDA220092
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Fri 27 Feb 2026🇺🇸 FDA approval
FDA approves Prezcobix (cobicistat, darunavir and cobicistat, darunavir ethanolate): new dosage form
Janssen Prods; NDA220092; New dosage form; tablet, for suspension · source
Same substance in other markets
- 🇪🇺 Symtuza Authorised · Janssen-Cilag International
- 🇪🇺 Rezolsta Authorised ·
- 🇪🇺 Genvoya Authorised · Gilead Sciences Ireland UC
- 🇪🇺 Stribild Authorised · Gilead Sciences Ireland UC
- 🇪🇺 Evotaz Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Tybost Authorised · Gilead Sciences Ireland UC
Follow Prezcobix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.